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Abstract
Background—Human papillomavirus (HPV) testing as primary cervical cancer screening has 
not been studied in Caribbean women. We tested vaginal self-collection versus physician cervical 
sampling in a population of Haitian women.
Methods—Participants were screened for high-risk HPV with self-performed vaginal and 
clinician-collected cervical samples using Hybrid Capture 2 assays (Qiagen, Gaithersburg, 
Maryland). Women positive by either method then underwent colposcopy with biopsy of all 
visible lesions. Sensitivity and positive predictive value were calculated for each sample method 
compared to biopsy results, with kappa statistics performed for agreement. McNemar’s tests were 
performed for differences in sensitivity at ≥ cervical intraepithelial neoplasia (CIN)-I and ≥ CIN-
II.
Results—Of 1845 women screened, 446 (24.3%) were HPV-positive by either method, 
including 105 (5.7%) only by vaginal swab and 53 (2.9%) only by cervical swab. Vaginal and 
cervical samples were 91.4% concordant (κ= 0.73 [95% CI: 0.69 – 0.77], p < 0.001). Overall, 133 
HPV-positive women (29.9%) had CIN-I, while 32 (7.2%) had ≥ CIN-II. The sensitivity of 
vaginal swabs was similar to cervical swabs for detecting ≥ CIN-I (89.1% vs 87.9%, respectively, 
p=0.75) lesions and ≥ CIN-II disease (87.5% vs 96.9%, p=0.18). Eighteen of 19 cases of CIN-III 
and invasive cancer were found by both methods.
Conclusions—HPV screening via self-collected vaginal swabs or physician-collected cervical 
swabs are feasible options in this Haitian population. The agreement between cervical and vaginal 
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samples was high, suggesting vaginal sample-only algorithms for screening could be effective for 
improving screening rates in this under-screened population.
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Introduction
Worldwide, invasive cervical cancer is the second most common cancer in women ages 15–
44 years.1 Latin America and the Caribbean have age-adjusted incidence rates of cervical 
cancer ranging from 20 to 80 per 100,000 women per year and account for greater than 80% 
of the disease burden within the Americas.2–4 Recent World Health Organization estimates 
for cervical cancer incidence in Haiti from 2000 and 2012 have varied between an age-
standardized rate of 24.9 and 93.9 per 100,000 women annually.4,5
Cervical cancer is a preventable disease caused by the sexual transmission of oncogenic 
types of human papillomavirus (HPV) infection.6 In low-resource regions, barriers such as 
high infrastructure costs, manpower challenges, and poor patient surveillance mechanisms 
frequently prevent implementation of cervical cancer screening programs.7 With recent 
technological advancements in cervical cancer screening methods, however, cervical cancer 
incidence can be significantly reduced through high-sensitivity primary screening methods 
that are self-administered and cost-effective.7–13 This includes HPV testing, which can 
reduce the incidence and mortality of cervical cancer relative to other methods, even if 
performed only once in a woman’s lifetime.7
Because HPV testing has the potential advantage of allowing self-collection of specimens, 
several international studies have compared self-sampling of vaginal specimens against 
clinician-collected cervical samples for high-risk HPV (HR-HPV) detection.8–15 In these 
studies, self-sampling has been nearly as sensitive as clinician-obtained cervical samples and 
more sensitive than cytology for the detection of cervical intraepithelial neoplasia (CIN) for 
lesions of high-grade CIN-II or higher (CIN-II+).16–19 Given the high sensitivity of HPV 
testing for CIN-II+ detection, the acceptability of self-sampling for patients, and the 
reduction in the number of clinicians required for a pelvic-based screening program, studies 
suggest use of vaginal self-sampling can increase access to cancer screening in resource-
limited settings.7,10,13,18
In Haiti, physicians are relatively few, preventive health programs are limited, and the 
formal health care system reaches only 60% of the population.20 In many similar resource-
limited settings, cervical cancer prevention is not a priority. However, in 2011, the Haitian 
Ministry of Health (MSPP) declared cervical cancer prevention a national priority, and a 
committee was formed in 2014 to review national cervical cancer screening guidelines. As a 
primary screening method involving vaginal HPV self-screening is being considered by this 
committee as an option to increase cervical cancer screening rates and there are no existing 
studies in a population of Caribbean women, we sought to test the feasibility of 
implementing HPV screening as primary testing for cervical cancer within a cohort of 
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women in Port-au-Prince, Haiti. Additionally, we sought to compare vaginal self-sampling 
screening methods against physician-administered cervical screening methods.
Materials and Methods
Population Studied
Two clinics in Port-au-Prince, Haiti, served as the testing locations for this study. The first is 
a freestanding clinic which screens approximately 4,000 women annually for cervical cancer 
using HPV testing. The second clinic is located within a women’s reproductive health 
facility in the city’s government district and has laboratory capabilities. A convenience 
sample of women were recruited through direct clinic referral through a standardized 
process and word-of-mouth. Women between the ages of 25 and 65 years who had engaged 
in vaginal intercourse at least once during their lifetimes were eligible. Exclusion criteria 
included current pregnancy, prior hysterectomy, or active menstruation. Women excluded 
for menstruation were asked to return for testing after the cessation of their menses.
Ethical Considerations and IRB Approval
Trained health workers versed in the study protocol guided participants through study 
documents in the Haitian Creole language. Consent forms written in Haitian Creole and 
English were provided to participants and orally administered as needed. The study was 
approved by the Institutional Review Board (IRB) at the Duke University School of 
Medicine (Pro00031654) as well as the Misyon Sante Fanmi Ayisyen IRB in Haiti to ensure 
cross-cultural ethical standards were met.
Initial study visit
Participants were assigned a randomly-generated ID number, which was placed on an ID 
card and used for the entirety of the study and database. Participants were then met by the 
study nurse who oriented them to the procedures involved in the collection of two types of 
high-risk HPV (HR-HPV) samples: 1) self-performed samples; and 2) clinician-performed 
samples.
HPV testing
Both self-performed vaginal samples and clinician-performed cervical samples were 
obtained using a Dacron brush (Qiagen, Gaithersburg, Maryland). Nurses instructed the 
participants to self-collect their specimens at the clinic by inserting the brush into the vagina 
and rotating the brush three times. After performing self-collection, a clinician placed a 
vaginal speculum and obtained a cervical sample by inserting a clean brush 1–1.5 cm into 
the cervical os and rotating three times. All samples were placed into HPV DNA collection 
tubes (Specimen Transport Medium, Qiagen, Gaithersburg, Maryland) and sealed with a 
paraffin secured lid for storage and transport. The two samples were identified by type by 
differently colored stickers labeled with ID numbers and the testing date.
Boggan et al. Page 3














Weekly, de-identified HR-HPV brush samples were collected from participating clinics and 
mailed to a pathology laboratory in Bremerton, Washington. Vaginal and cervical samples 
were tested for the presence of one or more of 13 high-risk HPV genotypes (16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, and 68) using the Hybrid Capture 2 High-Risk HPV DNA 
Test™ (HC2, Qiagen, Gaithersburg, Maryland) pool assay.21
Follow-up
Patients were scheduled for a return appointment to receive results of HPV testing. At that 
visit, HR-HPV-negative women were asked to return for follow-up screening in a year, 
while women who were HR-HPV-positive by either method were immediately scheduled for 
colposcopy and biopsy. Nurses attempted to contact women who failed to return for results 
and/or follow-up appointments within approximately one week of the missed appointment.
Colposcopy and biopsy
All patients with at least one HPV positive result from either vaginal or cervical samples 
who received these results and returned for the prescheduled follow-up visit underwent 
colposcopy and biopsy. Trained physicians performed colposcopies and biopsies. Single 
biopsies were taken from each visible lesion seen by colposcopy and by endocervical 
curettage if the squamocolumnar junction was not entirely visible. Visible lesion locations 
were recorded. Specimens were stored in vials of formaldehyde with parafilm-secured lids 
to prevent leakage during shipment to the diagnostic facility in Washington State.
Pathology
Cervical biopsy specimens were collected and stored in 10% neutral buffered formalin for 
fixation and preservation. The specimens were shipped to PAKC laboratories (Silverdale 
Washington), where the specimens were processed and hematoxylin and eosin (H&E) 
stained. After staining, whole slide images of each slide were generated using a Leica 
SCN400 scanning system. Each whole slide image was then uploaded to a secure cloud 
image server, where six pathologists with expertise in cervical pathology from PathForceDx 
(Bremerton, Washington) rendered primary diagnoses via whole slide images accessed using 
Simagis viewing software (Smart Imaging Technologies, Houston, TX). Diagnoses were 
rendered using the Lower Anogenital Squamous Terminology (LAST) 2012 consensus 
recommendations.22 Results were given with a two-tiered classification system (LGSIL and 
HGSIL) for low-grade and high-grade squamous intraepithelial lesions with corresponding 
older classifications (HPV effect, CIN-I, CIN-II, CIN-III) provided for diagnostic 
clarification. All diagnostic reports were rendered using the cloud-based reporting system 
LIS Anywhere (Xifin corp., San Diego, California).
Treatment
Given potential loss to follow-up, a “see-and-treat” protocol was offered to women with 
suspicious lesions during the colposcopy examination if there was a concern about their 
ability to return. Patients in this group with lesions that were not consistent with invasive 
cancer were treated with cryotherapy in the clinic, while those with invasive cancer were 
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referred for other management. After biopsy results returned, women were scheduled for 
cryotherapy treatment, as appropriate, or were referred to the Groupe de Support Contre le 
Cancer for assistance with patient navigation to other treatment facilities.
Data analysis
Descriptive statistics were performed for vaginal and cervical HPV positivity, stratified by 
level of disease observed in biopsy samples. Sensitivity and positive predictive value (PPV) 
were calculated for cervical and vaginal HR-HPV assays compared to biopsy results.
Kappa statistics were performed for agreement between self-collected and clinician-
collected samples. For patients who were biopsied in multiple cervical quadrants, the highest 
level of disease found in any of the quadrants was reported and used for analysis. 
Differences in sensitivity for ≥ CIN-I and ≥ CIN-II disease were compared using 
McNemar’s test for paired samples. All analyses were considered significant at a p-value < 
0.05 and conducted using STATA v.11 (College Station, Texas).
Results
Study Population
A total of 1,845 women enrolled in the study, with a median age of 41 years and age of 
sexual debut of 19 (Table 1). Although most women (62.4%) reported only one or two 
sexual partners in their lifetimes, half (50.8%) of the women’s partners had children with 
other women. Of the women enrolled, cervical screening data are available on 1,836 women.
HPV Results
Overall, 446 women (24.3%) were HR-HPV-positive and referred for further testing (Table 
2). Vaginal self-swabs resulted in a higher detection rate for HPV, with 53 women positive 
on only their cervical sample (11.9% of positive women) and 105 (23.5%) on only their 
vaginal sample. Among HPV-positive women, 288 (64.6%) tested positive by both vaginal 
and cervical HPV collection methods. Overall concordance between the vaginal and cervical 
testing was 91.4% (1678 of 1836) with good strength of agreement (κ= 0.73 [95% CI: 0.69 – 
0.77], p < 0.001). In patients with ≥ CIN-II disease, 27 of all 32 cases with visible lesions 
(84.4%), including all four cases of cancer, were HPV-positive by both methods (Table 3).
HPV Screen Compared to Biopsy
A total of 75 of 446 HR-HPV-positive women (16.8%) did not return for the recommended 
follow-up appointment for colposcopy and biopsy. Women who did not return were younger 
(35.2 vs 39.5 years, p<0.01), had first pregnancies at younger ages (17.2 vs 20.1 years, 
p<0.01), and were less likely to be married (p<0.05) than women who returned. Of the 
remaining 371 women who returned for these appointments and underwent colposcopy, 4 
had non-diagnostic biopsy results and one did not receive a biopsy. These 5 women were 
excluded from the analysis, yielding a final sample size of 366 women with at least one 
positive HR-HPV test who underwent biopsy. This included a total of 48 women (13.1% of 
those with biopsies) who had a positive cervical swab but negative vaginal swab, 73 women 
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who had a positive vaginal swab but negative cervical swab (19.9%), and 245 women who 
had both positive cervical and vaginal swabs (66.9%, Table 3).
Overall, 25 women (5.6%) had normal biopsy results, while 165 (37.1%) had dysplasia on 
biopsy. A total of 133 women (29.9%) had CIN-I disease, while 32 (7.2%) had ≥ CIN-II 
disease (Table 3).
The sensitivity of vaginal swabs for detecting ≥ CIN-II was 87.5% (95% CI 84.1%–90.9%) 
compared to 96.9% (95% CI 95.1–98.7%) for cervical swabs (Figure 1, p=0.18). The PPV 
for vaginal swabs for detecting ≥ CIN-II was 8.8% (95% CI 5.9–11.7%) compared to 10.6% 
(95% CI 7.4% – 13.7%) for cervical swabs. The sensitivity of vaginal swabs for detecting ≥ 
CIN-I disease was 89.1% (95% CI 85.9–92.3%) compared to 87.9% (95% CI 84.5–91.2%) 
for cervical swabs (p=0.75). The PPV for vaginal swabs for detecting ≥ CIN-I was 46.2% 
(95% CI 41.1–51.3%) compared to 49.5% (95% CI 44.4–54.6%) for cervical swabs. Both 
methods were highly sensitive for ≥ CIN-III disease, with 18 of 19 found by both methods 
and the remaining case found by vaginal swab.
Discussion
This study demonstrates the feasibility of performing HR-HPV screening as a primary 
cervical cancer screening modality in a low-resource, Haitian population. Women in this 
study volunteered to participate in vaginal self-screening for HPV. The sensitivity of HPV 
screening for detecting ≥ CIN-II in this study was 87.5% for vaginal samples and 96.9% for 
cervical samples and our kappa concordance value was similar to others reported in the 
literature.16,19 The agreement between cervical and vaginal samples was high, suggesting 
vaginal sample-only algorithms could be implemented in this under-screened and high-risk 
population to improve access to cervical cancer screening.
The prevalence of HPV in this population was 24.3%. Compared to other HPV studies in 
low-resource populations amongst similarly-aged women, our Haitian population had an 
almost three-fold higher rate of HPV positivity than in a population in Mexico and had 
comparable rates to populations in South Africa and Tanzania.18,23,24 Women in this study 
had a relatively low number of lifetime sexual partners and late age of sexual debut, 
minimizing the chance of spectrum bias for cervical disease. Additionally, the overall rate of 
HPV positivity is consistent with the rate of cervical cancer observed in Haitian women.
This difference between sensitivities in vaginal and cervical swabs for ≥ CIN-II disease is 
comparable to some studies with primarily healthy populations included in a recent 
review.19 In this population, assuming no verification bias, screening only with HR-HPV 
testing vaginally and referring only HPV positive women by vaginal screen for further 
evaluation would have missed 12.5% of ≥ CIN-II disease and 14.2% of treatable HSIL 
lesions. In comparison, clinician-collected cervical HPV screening would have missed 3.5% 
of treatable HSIL lesions found by self-collection.
In an ideal research study, we would have evaluated HPV-negative women with colposcopy 
and random cervical biopsy to eliminate verification bias; however, this was deemed 
unacceptable by our clinical partners. Performing corrections for verification bias per Begg 
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and Greenes on our sample yields sensitivities for ≥ CIN-II of 22.3% for vaginal and 63.7% 
for cervical specimens with specificities of 78.7% and 82.9%; however, this excludes all 
women who were HPV-negative by both samples.25,26 As a result, these corrections differ 
markedly and overcorrect compared to studies in which women with HPV negative results 
by HC2 were also evaluated, presumably because women testing positive by only one 
sample differ clinically regarding cervical pathology than women negative by both 
samples.8,27,28 In studies by Belinson et al. and Holanda et al. in which HPV-negative 
women underwent colposcopy and biopsy, sensitivities for vaginal samples were >83% 
while those for cervical samples were >88%.8,27
Even though cervical samples have higher sensitivies for CIN-II+ detection, if programs that 
implemented vaginal swabs increased the overall rate of screening given the insufficiency of 
current infrastructure to provide clinician-based cervical sampling, more disease may be 
detected using vaginal swabs compared to cervical swabs. Furthermore, the sensitivity of 
HPV screening by vaginal swabs is higher than conventional cytology, which has a 
sensitivity of approximately 60% and is the current standard of care in Haiti.14,17,19,29 
Additionally, the overall acceptability of this self-sampling approach makes it appealing for 
use in remote, under-screened communities.
As we have developed a relationship with a national network of women’s health facilities 
initially founded for HIV care (FOSREF, or Fondation pour la Santé Reproductrice et 
l’Education Familiale), we believe self-collection of vaginal swabs based in these available 
clinical settings represents a feasible next step for implementing cervical cancer prevention 
efforts. Similar integration of cervical cancer screening and treatment has been successfully 
added to existing HIV clinic infrastructure in other low-resource settings.30 Thereafter, 
expanding screening further with trained community health workers referring HPV-positive 
women to existing clinic infrastructure could then more efficiently use available health 
resources via task shifting.31 Such efforts to utilize community health personnel to increase 
cervical cancer screening have been successful in low-resource settings and for underserved 
populations in developed nations.32–34
Our loss to follow-up among HPV-positive women was 16.8%. Women who did not return 
for follow-up colposcopy and biopsy were younger at the time of their first pregnancy and 
their clinical evaluation. They were also less likely to be married than returning HPV-
positive women in our cohort, which may suggest that they have less stable social support. 
Targeted outreach to this population, particularly during screening intake, may increase the 
number of HPV-positive women ultimately receiving treatment for cervical lesions.
This study is the first to demonstrate the successful implementation of HPV self-screening in 
a Caribbean population. If HPV screening was instituted as the primary cervical cancer 
screening strategy within Haiti, the number of women requiring pelvic examination for 
screening may be reduced by 75%. This would enable limited public health resources to be 
targeted to women with the highest risk of having clinically-significant lesions. These data 
will be used to inform upcoming national cervical cancer screening guidelines by the MSPP.
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One limitation of this study is that only women who were HPV-positive were reflexively 
triaged to colposcopy, as referenced above. In future studies, we will refer a subset of 
women with negative HPV results to colposcopy to adjust for verification bias. Additionally, 
the use of colposcopy in a two-visit algorithm led to a loss to follow-up rate of 16.8% of 
HPV-positive women, emphasizing the need for highly specific biomarkers to be used for 
the triage of HPV-positive women, point-of-care colposcopy techniques, screen-and-treat 
algorithms and development of better follow-up systems. In the absence of a rapid, highly 
sensitive/specific, same-day HPV screening test, targeted efforts to educate younger, single 
women may positively impact this attrition rate. Next, women who present for clinical 
examination may not be representative of the population; however, the age, sexual debut, 
and number of partners in this cohort indicate no unusual risk factors for cervical disease. 
Finally, testing for HPV was performed in the US after shipping of specimens; therefore, we 
are currently working to be able to perform this testing within Haiti to eliminate the need for 
shipping.
The major implication of the feasibility of HPV self-screening strategies in this population is 
that this screening methodology might be more easily disseminated in remote, rural Haitian 
communities than conventional methodologies involving cytology or VIA which are 
dependent upon the receipt of a pelvic examination. Future research will include the 
additional utilization of a battery-powered colposcope providing up to 8x magnification 
(CerviScope) compared to conventional (25x magnification) colposcopy and VIA (1x 
magnification) for treatment for HPV positive women.
In conclusion, HPV screening was feasible in a large population of women in a low-
resource, Caribbean setting, which should allow for development of screen-and-treat 
strategies to optimize public health resources using HPV self-sampling.
Acknowledgments
Conflicts of Interest and Source of Funding:
Jennifer S. Smith has received research grants and/or served on paid advisory boards for Hologic, BD Diagnostics, 
Trovagene and QIAGEN over the past five years. For the remaining authors, none were declared. QIAGEN 
(Gaithersburg, Maryland) provided HPV testing kits and specimen transport media and the Center for Aids 
Research (CFAR Parent Grant Number 2P30 AI064518-08) and Duke University (AI064518) provided funding for 
this study. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, 
or writing of the report.
References
1. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cancer. Human 
Papillomavirus and Related Cancers in World: Summary Report Update. 2010 Nov 15. 2010. 
2. Villa LL. Cervical cancer in Latin America and the Caribbean: the problem and the way to 
solutions. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1409–1413. [PubMed: 22956726] 
3. National Cancer Institute. SEER Stat Fact Sheets: Cervix Uteri Cancer. 2013
4. Ferlay, J.; Bray, F.; Pisani, P., et al. GLOBOCAN 2000: Cancer Incidence, Mortality and 
Prevalence Worldwide. Lyon, France: IARC Press; 2001. 
5. Ferlay, J.; Soerjomataram, I.; Ervik, M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and 
Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for 
Research on Cancer; 2013. Available from: http://globocan.iarc.fr. [Accessed May 13, 2014]
Boggan et al. Page 8













6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of 
invasive cervical cancer worldwide. J Pathol. 1999; 189:12–19. [PubMed: 10451482] 
7. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer 
in low- and middle-income developing countries. Bull World Health Organ. 2001 Jan; 79(10):954–
962. [PubMed: 11693978] 
8. Holanda F Jr, Castelo A, Veras TM, et al. Primary screening for cervical cancer through self 
sampling. Int J Gynaecol Obstet. 2006 Nov; 95(2):179–184. [PubMed: 16997304] 
9. Karwalajtys T, Howard M, Sellors JW, et al. Vaginal self sampling versus physician cervical 
sampling for HPV among younger and older women. Sex Transm Infect. 2006 Aug; 82(4):337–339. 
[PubMed: 16877589] 
10. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in 
developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008 
Oct; 9(10):929–936. [PubMed: 18805733] 
11. Bhatla N, Dar L, Patro AR, et al. Can human papillomavirus DNA testing of self-collected vaginal 
samples compare with physician-collected cervical samples and cytology for cervical cancer 
screening in developing countries? Cancer Epidemiol. 2009 Dec; 33(6):446–450. [PubMed: 
19931499] 
12. Belinson JL, Du H, Yang B, et al. Improved sensitivity of vaginal self-collection and high-risk 
human papillomavirus testing. Int J Cancer. 2012 Apr 15; 130(8):1855–1860. [PubMed: 
21630255] 
13. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA Test as a 
cervical cancer primary screening method. J Natl Cancer Inst. 2012 Feb 8; 104(3):178–188. 
[PubMed: 22271765] 
14. Salmeron J, Lazcano-Ponce E, Lorincz A, et al. Comparison of HPV-based assays with 
Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes 
Control. 2003 Aug; 14(6):505–512. [PubMed: 12948281] 
15. Seo SS, Song YS, Kim JW, et al. Good correlation of HPV DNA test between self-collected 
vaginal and clinician-collected cervical samples by the oligonucleotide microarray. Gynecol 
Oncol. 2006 Jul; 102(1):67–73. [PubMed: 16375952] 
16. Petignat P, Faltin DL, Bruchim I, et al. Are self-collected samples comparable to physician-
collected cervical specimens for human papillomavirus DNA testing? A systematic review and 
meta-analysis. Gyneco Oncol. 2007 May; 105(2):530–535.
17. Twu NF, Yen MS, Lau HY, et al. Type-specific human papillomavirus DNA testing with the 
genotyping array: a comparison of cervical and vaginal sampling. Eur J Obstet Gynecol Reprod 
Biol. 2011 May; 156(1):96–100. [PubMed: 21288625] 
18. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for 
human papillomavirus testing in cervical cancer prevention (MARCH): a community-based 
randomised controlled trial. Lancet. 2011 Nov 26; 378(9806):1868–1873. [PubMed: 22051739] 
19. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-
collected specimens: a review on the clinical accuracy and impact on population attendance in 
cervical cancer screening. Int J Cancer. 2013 May 15; 132(10):2223–2236. [PubMed: 22907569] 
20. Prins A, Kone A, Nolan N, et al. USAID/Haiti Maternal and Child Health and Family Planning 
Portfolio Review and Assessment, August 2008. 2008
21. Clavel C, Masure M, Bory JP, et al. Hybrid Capture II-based human papillomavirus detection, a 
sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. 
Br J Cancer. 1999; 80(9):1306–1311. [PubMed: 10424730] 
22. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology 
standardization project for HPV-associated lesions: Background and consensus recommendations 
from the College of American Pathologists and the American Society for Colposcopy and Cervical 
Pathology. Arch Pathol Lab Med. 2012; 136:1266–1297. [PubMed: 22742517] 
23. Denny L, Kuhn L, Hu CC, et al. Human papillomavirus-based cervical cancer prevention: long-
term results of a randomized screening trial. J Natl Cancer Inst. 2010; 102(20):1557–1567. 
[PubMed: 20884893] 
Boggan et al. Page 9













24. Dartell M, Rasch V, Munk C, et al. Risk factors for high-risk human papillomavirus detection 
among HIV-negative and HIV-positive women from Tanzania. Sex Transm Dis. 2013; 40(9):737–
743. [PubMed: 23949589] 
25. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to 
selection bias. Biometrics. 1983 Mar; 39(1):207–215. [PubMed: 6871349] 
26. Greenes RA, Begg CB. Assessment of diagnostic technologies. Methodology forunbiased 
estimation from samples of selectively verified patients. Invest Radiol. 1985 Oct; 20(7):751–756. 
[PubMed: 3835974] 
27. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province cervical cancer screening study: a 
cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol 
Oncol. 2001; 83(2):439–444. [PubMed: 11606114] 
28. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province cervical cancer screening study II: 
self-sampling for high-risk human papillomavirus compared to direct sampling for human 
papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer. 2003; 13(6):819–826. 
[PubMed: 14675319] 
29. Wright TC Jr, Denny L, Kuhn L, et al. HPV DNA Testing of Self-collected Vaginal Samples 
Compared With Cytologic Screening to Detect Cervical Cancer. JAMA. 2000; 283(1):81–86. 
[PubMed: 10632284] 
30. Mwanahamuntu MH, Sahasrabuddhe VV, Blevins M, et al. Utilization of cervical cancer screening 
services and trends in screening positivity rates in a ‘screen-and-treat’ program integrated with 
HIV/AIDS care in Zambia. PLoS One. 2013; 8(9):e74607. [PubMed: 24058599] 
31. World Health Organization. Task shifting: rational redistribution of tasks among health workforce 
teams: global recommendations and guidelines. Geneva, Switzerland: World Health Organization; 
32. O’Brien MJ, Halbert CH, Bixby R, et al. Community health worker intervention to decrease 
cervical cancer disparities in Hispanic women. J Gen Intern Med. 2010; 25(11):1186–1192. 
[PubMed: 20607434] 
33. Elliott PF, Belinson SE, Ottolenghi E, et al. Community health workers, social support and cervical 
cancer screening among high-risk groups in rural Mexico. J Health Care Poor Underserved. 2013; 
24(4):1448–1459. [PubMed: 24185143] 
34. Arrossi S, Thouyaret L, Herrero R, et al. Effect of self-collection of HPV DNA offered by 
community health workers at home visits on uptake of screening for cervical cancer (the EMA 
study): a population-based cluster-randomised trial. Lancet Glob Health. 2015; 3(2):e85–e94. 
[PubMed: 25617202] 
Boggan et al. Page 10














Sensitivity for Detecting Different Levels of Cervical Dysplasia, by Specimen Source
Boggan et al. Page 11

























Boggan et al. Page 12
Table 1
Demographics of Study Participants (n=1,836)
Age in years (interquartile range (IQR)) 41 (34, 48)
Age at sexual debut in years (IQR) 19 (17, 22)
Age at menarche in years (IQR) 14 (13, 16)
Age at first pregnancy in years (IQR) 21 (18, 25)
Number of lifetime partners (SD) 2.5 (2.5)
Number of lifetime pregnancies (SD) 4.1 (2.9)
Number of vaginal deliveries (SD) 2.7 (2.3)
Number of Caesarean sections (SD) 0.2 (0.5)
Number of therapeutic abortions (SD) 0.8 (1.2)
Number of miscarriages (SD) 0.4 (0.8)
Number married (%) 936 (51.0)
Number unmarried but living with a partner (%) 533 (29.1)
IQR = interquartile range, SD = standard deviation
*
All variables with interquartile ranges (IQR) represent medians, while those with standard deviations (SD) represent means.
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Table 2






Vagina Positive 288 (15.7%) 105 (5.7%) 393 (21.4%)
Vagina Negative 53 (2.9%) 1390 (75.7%) 1443 (78.6%)
Total 341 (18.6%) 1495 (81.4%) 1836 (100.0%)
*
κ = 0.73 for agreement for HPV positivity between vaginal and cervical samples
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Table 3








Cervix − Both +
Normal 2 (0.4%) 13 (2.9%) 10 (2.2%) 25 (5.6%)
HPV Cytopathic Effect 28 (6.3%) 40 (9.0%) 108 (24.3%) 176 (39.6%)
CIN-I 14 (3.1%) 19 (4.3%) 100 (22.5%) 133 (29.9%)
CIN-II 4 (0.9%) 0 (0.0%) 9 (2.0%) 13 (2.9%)
CIN-III 0 (0.0%) 1 (0.2%) 14 (3.1%) 15 (3.4%)
Cancer / Invasive Carcinoma 0 (0.0%) 0 (0.0%) 4 (0.9%) 4 (0.9%)
Non-diagnostic† 1 (0.2%) 2 (0.4%) 1 (0.2%) 4 (0.9%)
Lost to Follow-Up 4 (0.9%) 30 (6.7%) 41 (9.2%) 75 (16.9%)
Total (%)§ 53 (13.1%) 105 (19.9%) 287 (66.9%) 445 (100.0%)
¶
HPV positive women were noted as having samples positive from only cervical specimens (Cervix + / Vagina −), only vaginal specimens (Vagina 
+ / Cervix −), or cervical and vaginal specimens (Both +).
§
One patient positive by both cervical and vaginal samples did not have biopsy performed.
†
These biopsies were uninterpretable.
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